CA2053253C - New aryl-and heteroarylethenylene derivatives and process for their preparation - Google Patents

New aryl-and heteroarylethenylene derivatives and process for their preparation Download PDF

Info

Publication number
CA2053253C
CA2053253C CA002053253A CA2053253A CA2053253C CA 2053253 C CA2053253 C CA 2053253C CA 002053253 A CA002053253 A CA 002053253A CA 2053253 A CA2053253 A CA 2053253A CA 2053253 C CA2053253 C CA 2053253C
Authority
CA
Canada
Prior art keywords
cyano
formula
ring system
tetrahydronaphth
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002053253A
Other languages
French (fr)
Other versions
CA2053253A1 (en
Inventor
Franco Buzzetti
Antonio Longo
Maristella Colombo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL filed Critical Farmitalia Carlo Erba SRL
Publication of CA2053253A1 publication Critical patent/CA2053253A1/en
Application granted granted Critical
Publication of CA2053253C publication Critical patent/CA2053253C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

Aryl- and heteroarylethenylene derivatives of formula (I) wherein Y is a mono-or bicyclic ring system chosen from (A), (B), (C), (D), (E), (F) and (G); R is a group of formula (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j) in which R3 is -OH or -NH2 and Ph means phenyl; R1 is hydrogen, C1-C6 alkyl or C2-C6 alkanoyl; R2 is hydrogen, halogen, cyano or C1-C6 alkyl; n is zero or an integer of 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A); it is zero, 1 or 2 when Y is a ring system (B), (E), (F) or (G); or it is zero or 1 when Y is a ring system (C) or (D);
and the pharmaceutically acceptable salts thereof;
and wherein each of the substituents R, OR1 and R2 may be independently on either of the aryl or heteroaryl moieties of the bicyclic ring system (A), (E), (F) and (G), whereas only the benzene moiety may be substituted in the bicyclic ring system (B), are useful as tyrosine kinase activity inhibitors.

Description

Title of the invention:
N~W ARYL- AND F-iETEROARYLETHENYLENE DERIVATIVES AND PROCESS rnR
THEIR PREPARATION
The present invention relates to new aryl- and heteroaryl-S ethenylene derivatives, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents.
The present invention provides compounds having the following general formula (I) D
( OR1 )n ( I ) r, 1G wherein Y is a mono- or bicyclic ring systems chosen from (A) and (B) (A) (F3) ..
_r c 2.
R is a group of formula (a) , (b) , (c) , (d) , (i) or (j ) N ~N N
-CH=~-COR3 -CH=C-CN -CH=~-CSNH2 ~(a) (b) (c) -CH=CH-COR3 (d) COR
-CHaC~~3 'OH
(i) N
-CH=~ ~ OH
(j) in which R3 is -OH or -NH2;
R1 is hydrogen, C1-C~ alkyl or C2-C6 alkanoyl; RZ is hydrogen, halogen, cya.-:o or CI-C6 alkyl;
n is zero or an integer of 1 to 3: n is zero or an integer of 1 to 3 when Y is a ring system (A) and it is zero, 1 or 2 wizen Y is a ring system (B); and the pharmaceutically acceptable salts thereof; and wherein each of the substituents R, OR1 and RZ may be independently on either of the aryl moieties of the bicyclic ring system (A) whereas only the benzene moiety may be substituted in the bicyclic ring system (B); and with the provisos that:
(i) when Y is a .ring system (A), R is other than a group (a) , (b) or (d) ,; and (ii) the compound of formula (I) is not 1,2,3,4-tetrahydro-5-naphthlene acrylic acid, or 1,2,3,4-tetrahydro-6-naphtha7_ene acrylic acid.
The invention inr_ludes within its scope all the possible isomers, stereoisomers, in particular Z and E
isomers and their mi~a:ures, and the metabolites and the metabolic precursors or bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I).
The substituent R is preferably linked to position 1 or 2 in ring system I;A) and (B). The substituent Rz may be independently on either of the rings in the bicyclic ring systems (A) and (B).
-When Y is a bicyclic ring system as defined under (A) the -OR1 groups are preferably on the same benzene moiety as the R grou~~. In ring system (A) the substituent Rz is preferably located on the same 6-membered ring as the substituent -OR,, in the -ortho-, meta- or para-positic>n with respect to -OR1. Preferably Rz is located in a position ortho- or para- to -OR1.
A substituent -OR1 is preferably linked to position 1, 2, 3, 4, 5 or 8, i.n particular to position 1, 2, 3 or 4, in ring systems (F,) and (B) .

Of course only one of the substituent R, -OR1 and R2 can be linked t:o the same position in ring systems (A) and (B) . _ - -When n is 2 or 3, the -OR1 groups may be the same or different.
. The alkyl groups, and the alkyl moiety in the alkanoyl groups, may be a branched or straight alkyl chain.
A C1-C6 alkyl group is preferably a C1-C~ alkyl group, e.g.
methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl, in particular methyl or ethyl. A Cz-C6 alkanoyl group is preferably a CZ-C~ alkanoyl group, in particular acetyl, propionyl oz butyryl.
A halogen is, preferably, chlorine, bromine or fluorine, in particular bromine.
Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts, with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acids, or organic, e.g. acetic, propionic, glycolic, lactic, oxalic, malonic, malic, malefic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic .
acids, and salts with inorganic, e.g. alkali metal, especially sodium or potassium, bases or alkaline-earth metal, especially calcium or magnesium bases, or with organic bases, e.g. alkylamines, preferably triethyl-amine.
As stated above the present invention also includes within its scope pharmaceutically acceptable bio-precursors (otherwise known as prc>-drugs) of the compounds of formula (I), i.e. compounds which have a different formula to formula (I) above but which nevertheless upon administration ' to a human being are converted directly or indirectly _in vivo into a compound of formula (I). Preferred compounds of the invention are the compounds of formula (I) wherein, subject to the provisos, Y is a monocyclic or bicyclic ring system chosen from (A) and (B), a.s defined above;
R is a group of formula (a) , (b) , (c) , (d) , (i) or (j ) as defined above;
R1 is hydr~~gen, C1-C9 alkyl or C.,-C~ alkanoyl;
R2is hydrogen; and n is as defined above; or a pharmaceutically acceptable salt thereof.
More preferred compounds of the invention are the compounds of formula (I) wherein, subject to the provisos, Y is a bicyclic ring system of formula (A) or (B) as defined above;
R is a group of formula (a), (d), (i) or (j), as defined above ; Rl and Rz are hydrogen ; and n is zero or 1; or a pharmaceutically acceptable salt thereof.
The invention a7_so provides a compound for use as a tyrosine kinase inhibitor, and a pharmaceutical composition comprising a pharmaceutically acceptable adjuvant or diluent and an active principal, the said compound or said active principal each being a compound of general formula ( I: ) a (ORl)n (I) ~2 a wherein Y is a mono- or bicyclic ring system chosen from (A) and (B) / \ \
\ / /
( R is a group of formula (a) , (b) , (c) , (d) , (i) or (j ) -CH=C-COR3 -CH=C-CN -CH=C-CSNHZ
-CH=CH-COR3 ~COR3 (d) -CH= / , \ OH
-CH=~ ~ ~ OH
(i) G) in which R3 is -OH or -NH2; R1 is hydrogen, C1-C6 alkyl or C2-C6 alkanoyl; R2 is hydrogen, halogen, cyano or Cl-C6 alkyl; n is zero or an integer of _7_ 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A) and ._t is zero, 1 or 2 when Y is a ring system (B); or a pharmaceutically acceptable salt thereof; and wherein each of the substituent R, ORl and R2 may be :independently on either of the aryl moieties of the bicyclic ring sy:~tem (A) whereas only the benzene moiety may be substituted in the bicyclic ring system (B); and with the proviso that when Y is a ring system (A), R is other than a group (a), (b) or (d).
The invention further provides the use, in the preparation of a medicament for use as a tyrosine kinase inhibitor, of a compound of formula (I):
R
(ORI)n (I) K~
25 wherein Y is a mono- or bicyc:7_ic ring system chosen from (A) and (B) / ~~ \
\ , ~~ , /
\, (A) (B) _g-R is a group of formula (a) , (b) , (c) , (d) , (i) or (j ) -CH=C-COR3 -CH=G-CN -CH=C-CSNH2 (a) (b) ( -CH=CH-COR3 ~COR3 -CH=C
OH
-CH=~ ~ ~ OH
(i) G) in which R3 is -OH or -NH2; R1 is hydrogen, C1-C6 alkyl or CZ-C6 alkanoyl; R2 is hydrogen, halogen, cyano or Cl-C6 alkyl; n is zero or an integer of 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A) and it is zero, 1 or 2 when Y is a ring system (b); or a pharmaceutically acceptable'salt thereof; and wherein each of the substituent R, OR1 and R2 may be independently on either of the aryl moieties of the bicyclic ring system (A) whereas only the benzene moiety may be substituted in the bicyclic ring system (B).

f F _9_ Examples of specific compounds of the invention are the following compounds which, when appropriate, may be either Z- or E- diastereomers or Z, E- mixtures of said diastereomers:
2-cyano-3-(2-hydroxynaphth-1-yl)acrylamide;
2-cyano-3-(3-hydroxynaphth-1-yl)acrylamide;
2-cyano-3-(~-hydroxynaphth-1-yl)acrylamide;
2-cyano-3-(1-hydroxynaphth-2-yl)acrylamide;
2-cyano-3-(3-hydroxynaF>hth-2-yl)acrylamide;
2-cyano-3-(4-hydroxynaphth-2-yl)acrylamide;
2-cyano-3-(2-hydroxynap~hth-1-yl)acrylic acid;
2-cy ano-3-(3-hydroxynaphth-1-yl)acrylic acid;
2-cyano-3-(4-hydroxynaphth-1-yl)acrylic acid;
2-cyano-3-(1-hydroxynaphth-2-yl) acrylic acid;
2-cyano-3-(3-by droxynaphth-2-yl) acrylic acid;
2-cyano-3-(4-hydroxynaphth-2-yl) acrylic acid;
2-cyano-3-(2-hydro::y.naphth-1-yl)thioacrylamide;
2-cyano-3-(3-hydroxynaphth-1-yl)thioacrylamide;
2-cyano-3-(4-hydroxynap:~th-1-yl)thioacrylamide;
2-cyano-3-( 1-hydroxynap'.7th-2-yl )t2nioacrylamide;
2-cyano-3-(3-hydroxynap:hth-2-yl)thioacrylamide;
2-cyano-3-(4-hydroxynap:hth-2-yl)thioacrylamide;
2-(4-hydroxyphenyl)-3-(naphth-1-yl)acrylanide;
2-(4-hydroxyphenyl)-3-(n aphth-2-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(naphth-1-yl)acrylic acid;
2-(4-hydroxyphenyl)-3-(naphth-2-yl)acrylic acid;

::

2-cyano-3-(2-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylamide;
2-cy2no-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylamide;.
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylamide;
2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylarnide;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-cyano-3-(2-hydroxy-5,f~,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(4-hydroxy-5,fi,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(1-hydroxy-5,f>,7,8-tetrahydronaphth-2-yl)acrylic acid;
2-cyano-3-(3-hydroxy-5,E>,7,8-tetrahydronaphth-2-yl)acrylic acid;
2-cyano-3-(4-hydroxy-S,Es,7,8-tetra'~ydronaphth-2-yl)acrylic acid 2-cyano-3-(2-hydroxy-S,E.,7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(3-hydroxy-5,f:~,7,B-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(~-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)thioacrylamide;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)thioacrylamide;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)thioacrylar~ide;
2-(4-hydroxyphenyl)-3-~;5,5,7,8-tetrahydronaphth-1-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(5,6,7,B-tetrahydronaphth-1-yl)acrylic acid;
2-(4-hydroxyphenyl)-3-(.5,6,7,8-tetrahydronaphth-2-yl)acrylic acid;

and, if the case, the p;-~armaceutically acceptable salts thereof.
The compounds of the invention, and the pharmaceutically acceptable salts thereo:'', can be obtained by a prccess comprising the condensai:ion of an aldehyde of formula (II) /H
C~
W

(II) ( OR1 )n wherein Y, R1, R2 and n are as defined above with a compound of formula (a' ), (b' ), (c' ), (d' ) ~~...._., (i') or (j'), respectively, (a') (b') (c') (d~) COR
I CN

./
~H I
OH
(i' ) (.~' ) wherein R3 is as defined above; and, A., optionally converting the compound of formula (I) thus obtained into a different compound of formula (I) by (a) de-etherifying the compound of formula (I) wherein one or more R1 substituents are C1-C6 alkyl to form the corresponding different compound of formula (I) wherein one or more R1 substituents are hydrogen; by (b) acylating the compound of formula (I) wherein one or more R1 substituents are hydrogen to form the corresponding different compound of formula (I) wherein one or more R1 substituents are C2-C6 alkanoyl; or by (c) converting the compound of formula (I) in which R is a group of formula -CH=C(CN)-COOH or -CH=CH-COOH into the corresponding different compound of formula (I) in which R
is a group of formula -CH=C(CN)-CONH2 or -CH=CH-CONH2, respectively; and/or, B., optionally converting the compound of formula (I) into a pharmaceutically acceptable salt thereof, and/or, C., optionally converting a salt into a free compound; and/or, D., optionally separating a mixture of isomers of a compound of formula (I) into the single isomers. The reaction of a compound of formula (II) with a compound of formula (a'), (b'), (c'), (d'), (i') or (j'), is an analogy process which can be carried out according to known methods, as herebelow described; preferably in the presence of a basic catalyst, e.g. pyridine, piperidine, dimethylamine, or a suitable alkali metal hydroxide or alkoxide.
For example, the reaction of a compound of formula (II) with a compound of formula (a' ) , (b' ) or (c' ) , respectively, may be carried out under the conditions of the Knoevenagel reactions, as described e.g. by G. Jones in Organic Reactions 15, 204 (1967). Suitable catalyst are organic bases such as pyridine, piperidine or diethylamine.

12a The condensation may be performed in an inert organic solvent e.g. pyridine, ethanol, methanol, benzene or dioxane at temperature ranging from about 0°C to about 100°C.
Preferably the reaction is carried out in warm ethanol solution in the presence of piperidine catalyst.

, 5 _ 13 _ The reaction of a compound of formula (II) with a compound of formula (d') may be carried out according to the Knoe-venagel method as described above but using special conditions.
Especially higher reaction temperatures are used in consideration B of the f act that during the condensation also a decarboxylation occurs. For instance l:he condensation may be performed in an organic base such as pyridine (which at same time is solvent and catalyst) at temperatures ranging from about 50° to about 140°C.
The reaction of a compound of formula (II) with a compound of formula (i') may be carried out as described by R.E. Buckles et al. in J,p~,,Chem.Soc. 73, 4972 (1951). According to this method equimolar amounts of the aromatic aldehyde and the phenylacetic derivative are reacted in 3-5 mclequivalents of acetic anhydride in the presence of about 1 molequivalent triethylamine at temperatures ranging from about 100 to about 140°C.
The condensation of a compound of formula (II) with a compound of formula (j') may be carried out in alcoholic solution using a metal alkaxide, e.g;. sodium ethoxide, potassium t-butoxide, or a metal hydroxide, es.g. sodium hydroxide, as catalyst; at temperatures ranging from about 0°C to about 100°C. Preferably equimolar amounts of reactants are condensed in ethanol solution at room temperature in the presence of sodium ethoxide using about 1 molequivalent for each acidic hydrogen of the latter.
A compound of formula (I) can be converted into another compound of formula (I) according to known methods. For example the de-etherification of a compound of formula (I), wherein one or mare R1 substituen ~ areCl-C6 alkyl, so as to f substituents /a hydrogen may be performed by well known methods in organic chemistry. In the case of a phenolic methyl ether the cleavage can be carried out for example with boron tribromide as described by J.F.N. McOmie in Tetrahedron 24, 2289 (1968). It is advisable to use about 1 mole of boron tribromide for each ether /g~~ogether with an extra mol of reagent for each gr oup containing a potentially basic nitrogen or oxyge=n. The reaction may be performed in an inert organic solvent: such as methylene chloride, pentane inert, e.g.
or benzene under an / nitrogen atmosphere at temperatures rang-ing from about -78°C to about room temperature.
The acylation of a compound of formula (I) wherein one or more R1 5ub5tituent is hydrogen, so as to obtain a correspond-ing compound of formula (I) wherein one or more R1 substituent is a C2-C6 alkanoyl group, may be obtained by reaction with a reactive derivative of a suitable carboxylic acid, such as an anhydride or halide, in the presence of a basic agent, at temperatures ranging from about 0°C to about 50°C. Preferably the acylation is carried out by reaction with the respective anhydride in the presence of an organic base, such as pyridine.
Analogously the conversion of a compound of formula (I), N
wherein R is a group of formula -CH=C-COOH or -CH=CH-COON, into another compound of formula (I) wherein R is a group N
of formula -CH=~-CONH2 o:r -CH=CH-CONH2, respectively, may be carried out according to known methods. For example a reactive obtain a compound of formula (I) wherein one or more R1 ~' derivative of the carboxylic acid, e.g. a Suitable halide, preferably the chloride, can be reacted with aqueous ammoniu m hydroxide solution at a. temperature ranging from about 5°C to about 40°C.
The optional salification of a compound of formula (I) as well as the conversion of a salt into the free compound and the separation of a mixture of isomers into the single isomers may be carried out by conventional methods.
For example the separation of a mixture of geometric isomers, e.g. cis- and traps-isomers, may be carried out by fractional crystallization from a suitable solvent or by chromatography, either column chromatography or high pressure liquid chromato graphy.
The compounds of formula (II) may be obtained according to known methods from compounds of formula (III).
( OR1 )n (III) wherein Y, R1, R2 and n are as defined above.
For example the phenoli~_ compound of formula (III) may be treated with chloroform and alkali hydroxides in an aqueous or aqueous alcoholic solution according to the well known method of Reimer-Tiemann. Lf the atarting material is an aromatic methylether the method described by N.S. Narasimhan et al. in Tetrahedron S1, 1005 (175) can be applied. Accordingly the i - 15 -methylether of formula {III) is lithiated with butyl lithium in refluxing ether. Treatment of the organometallic compound with N-methylformanilide furnishes the formyl derivative.
The compounds of formu la (III) are known or maybe obtained by known methods from known compounds.
PHART~1ACOLC~Y
The compounds of the present invention possess specific tyrosine kinase inhib.ting activity. H ence they can be useful in the treatment of cancer ar.d other pathological proliferative conditions.
Recent studies on the molecular basis of neoplastic transforma-tion have identified a 1.'amily of genes, designed oncogenes, whose aberrant expression causes tumorigenesis.
For example, the RNA tumor viruses possess such an oncogene sequence whose expression determinesneoplastic conversion of infected cells. Several of their oncogene-encoded proteins, such as-pp60v-src~ p~Ogag-yes p130gag-fps and p70gag-fgr display protein tyrosine kinase activity, that is they catalyse the transfer of the ~ -phosphate from adenosine triphosphate (ATp) to tyrosine residues in protein substrate. In normal cells, several growth factor receptors, for example the receptors for PDGF, EGF, (~ -TGF and insulin, display tyrosine kinase activity.
Binding of the growth factor {GF) activates the receptor tyrosine kinase to undergo autophosphorylation and to phosphorylate closely adjacent molecules on tyrosine.
Therefore, it is thoughtthat the phosphorylation of these 1~ -tyrosine knase receptors plays an important role in signal transduction and that the principal function of tyrosine kinase activity in normal cells is to regulate cell growth.
Perturbation of this activity by oncogenic tyrosine kinase that are either overproduced and/or display altered sub-strate specificity may cause loss of growth control and/or neoplastic transformat:ion.Accon-i~ngly, a specific inhibitor o f tyrosine kinases can be useful in investigating the mechanism of carcinogenesis, cell proliferation and differen-nation and it can be effective in prevention and chemothe-rapy of cancer and in other pathological proliferative conditions.
The tyrosine specific protein kinase activity of these compounds is shown, e.g., by the f act that they are active in the in vitro test described by B. Ferguson et al., in J. Biol. Chem. 1985, 260, 3652.
The enzyme used is the Abelson tyrosine kinase p 60v abl Its production and isolation is performed according to a modification of the method of B. Ferguson et al. (ib~dem).
As substrate L7(-casein or (ValS)-angiotensin is used.
The inhibitor is preincubated with the enzyme for 5 min at 25°C. The reaction conditions are:
100 mM MOPS buffer, 10 mM MgCl2, 2~uM (~ -32P) ATP (6Ci/mmol), 1 mg/ml x -casein /an alternative substrate is (ValS) angiotensin II/ and 7.~~~ug/ml of enzyme in a total volume of 30 ~1 and pH 7Ø
The reaction is incubated for 10 min at 25°C.

t - 1.8 -Trichloroacetic acid precipitation of protein is followed by rapid filtration and quantification of phosphorylated substrate by a liquid scintillation counter. Alternatively the reaction mixture s subjected to sodium dodecyl sulfate - polyacrylamide eleci:rophoresis and the phosphorylated substrate measured by autoradiography or P32-counting of the excised spot.
In view of their high activity and low toxicity, the car~row,ds of the invention can be L.sed safely in medicine.
For example, the approximate acute toxicity (LD50) of the compounds of the invention in the mouse, determined by single administration of increasing doses and measured on the seventh day after the treatment was found to be negligible.
The compounds oi' the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar of film coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; paren-terally, e.g. intramuscularly, or by intravenous injection of infusion; or topically.
The dosage depends or: the age, weight, conditions of the patient and administration route; for example the dosage adopted for oral administration to adult humans may range from about 10 to about ISO-200 mg pro dose, from 1 to 5 times daily.
Of course, these dosage=_ regimens may be adjusted to provide the optimal therapeutic response.

The pharmaceutical compositions of the invention are usua:Lly prepared following conventional methods and are administered in a pharmaceutically suitable form.
For example, the solid oral forms may contain; together with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g, starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolicor~e; disaggregating agents, e.g. a starch, alginic acid, alginate; or sodium starch glycolate, efferve-scing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, ta.bletting sugar-coating or film-coating processes.
The liguid dispersion for oral administration may be e.g.
syrups, emulsions a-~d suspensions.
The syrup may contain as carrier, for example, saccharose or ' CA 02053253 2001-08-13 _ 20 _ saccharose with glycerine and/or mannitol and/or sorbitol.
The suspensions and t;he emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
The suspensions or sclutions for intramuscular injections may contain, together with the active compound, a pharma-ceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g, propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusion may contain -as carrier, for example, sterile water or, preferably, they may be in the form of sterile, aqueous, isotonic saline solutions.
The suppos::tories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
Compositions for topical application e.g., creams, lotions or pastes, can be prepared by admixing the active ingredient with a conventional o''~eaginous or emulsifying excipient.
The following examplea illustrate but do not limit the invention.

' CA 02053253 2001-08-13 - i - - 21 -Reference Example 1 2-cyano-3-(8-hydroxyquinolin-5-yl) acrylamide LI~Y = E, R -_ a, R1 = ;~2 = H, n = 1, R3= NH2I
A solution of 5-formyl--8-hydroxyquinoline(173 mg, 1 mmol), t. cyanoacetami.de (92 mg; 1.1 mmol) and piperidine (60 mg, 0.7 mmol) in absolute ethanol (20 ml) is heated for 4 h at 50°C. The reaction mixture is chilled to 0-5°C, the _.
precipitate filtered, t:he residue washed with ice-cooled ethanol and then dried under vacuum.
Pure title compound is so obtained in 70~ yield (167 mg).
Compounds of higher purity are obtained by crystallization from ethanol,m,p, 275° .
Cl3HgN302 requires: C E.5.27 H 3.79 N 17.56 found . C E5.15 H 3.65 N 17.49 MS m/z . 239 IR cm 1 (KBr) . 3100 - 3600 (NH,OH), 2200 (CN), 1690(C0NH2), 1610, 1590, 156D~ 1510 ( C = C ) Example 1 According to the prod=_dure of Reference Example 1 the following compounds can be prepared:
2-cyano-3-(2-hydroxynaphth-1-yl)acrylamide;
2-cyano-3-(3-hydroxynaphth-1-yl)acrylamide;
2-cyano-3-(4-hydroxynaphth-1-yl)acrylamide:
2-cyano-3-(1-hydroxynaphth-2-yl)acrylamide;
2-cyano-3-(3-hydroxynaphth-2-yl)acrylamide;
2-cyano-3-(4-hydroxynaphth-2-yl)acrylamide;

z-cyano-3-(2-hydroxy-5,5,7,8-tetrahydronaphth-1-yl)acrylamide;
8 2-cyano-3-(3-hydroxy-:5,6,7,B-tetrahydronaphth-1-yl)acrylamide;
2-cyano-3-1;4-hydroxy-!~,5,7,8-tetrahydronaphth-1-yl)acrylamide;
2-cyano-3-(1-hydroxy-E~,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-cyano-3-(3-hydroxy-Ep,6,7,8-tetrahydronaphth-2-yl)acrylamide;and 2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide~

Ex amr 1 e. 2 2-cyano-3-(2-hydroxynaphth-1-yl)thioacrylamide ~I, Y = A, R = c, R1 = R2 = N, n = 1~
A mixture of 2-hydroxy-1-naphthaldehyde (172 mg, 1 mmol), 2-cyanothioacetamide (110 mg, 1.1 mmol), N,N-diethylamino-ethanol (23 mg, 0.2 mmol) and 15 ml ethanol is stirred for 30 min at reflux under nitrogen. '''hen the mixture is chilled, the precipitate filtered ,warned with ice-cooled ethanol and dried in a vacuum-oven.'~us an a7-~~st pure title .compound is obtained in 85% yield (1080 mg). Recrystallization from ethanol furnishes very pure samples.
C14H10N20S requires: C 6f~,12 H 3.96 N 11.01 S 12.61 found . C 6E>.05 H 3.85 N 10.95 S 12.55 MS m/z . 254 IR cm 1 (KBr) . 3300 ;- 2500 (NN, OH), 2020 (CN), 1640 (C-N, N-N), 1600-1560-1510 (C = C) According to the above described procedure the following compounds can be prepared:
i 2-cyanc-3-(3-hydroxynapht:h-1-yl)thioacrylamide;
2-cyano-3-(4-hydroxynapht:h-1-yl)thioacrilamide;
2-cyano-3-(1-hydroxynaph;:h-2-yl)thioacrylamide;
2-cyano-3-(3-hydroxynapht:h-2-yl)thioacrylamide;
2-cyano-3-(4-hydroxynapht:h-2-yl)thioacrylamide;
2-cyano-3-(2-hydroxy-5,6,,7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(3-hydroxy-5,6,.7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(4-hydroxy-5,6"7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(1-hydrcxy-5,6"7,8-tetrahydronaphth-2-yl)thi~oacrylamide;
2-cyano-3-(3-hydroxy-5,6.,7,8-tetrahydronaphth-2-yl)thioacrylamide;and 2-cyano-3-(4-hydrcxy-5,6.,7,8-tetrahydronaphth-2-yl)thioacrylamide~

r s -Example 3 2-cyano-3-(1-hydroxynaphth-2-yl)acrylic acid (I, Y = A, R = a, R1 = R2 = H, R3 = OH, n = 1]
To a mixture of 1-hydroxy-2-naphthaldehyde (172rr~g,1 mmol ) and cyanoacetic acid (85 mg, 1 mmol) in dry dioxane (2 ml) piperidine (42 mg, 0.5 mmol) is added dropwise at O-5°C.
The mixture is kept overnight at room temperature.
The crystals formed are filtered and recrystallized from chloro-form. Thus 200 mg of pure title compound are obtained corresponding to g0/ yield.
C14N8N02requires: C 75.33 H 4.06 N 6.2B
found . C 75.20 H 3.95 N 6.15 MS m/z . 223 IR cm 1 (KBr) . 3300 - 2500 (COON , OH), 2200 (CN), _ 1690 (COOH), 1600-1560-1510 (C = C) Following the above reported procedure and starting from the appropriate aldehyde derivative the following compounds can be prepared:
2-cyano-3-(2-hydroxynaphth-1-yl)acrylic acid;
2-cyano-3-(:3-hydroxynaphth-1-yl)acrylic acid;
2-cyano-3-(4-hydroxynaphth-2-yl)acrylic acid;
2-cyano-3-(;3-hydroxynaphth-2-yl)acrylic acid;
2-cyano-3-(3-hydroxyna:phth-2-yl)acrylic acid;
2-cyano-3-(2-hydroxy-5,6,7,B-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;

.,.\

2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylic acid;
2-cyano-3-(3-hydroxy-5;,6,7,8-tetrahydronaphth-2-yl)acrylic acid; and 2-cyano-3-(4-hydroxy-5,6,7,B-tetrahydronaphth-~yl)acrylic acid', .
~xample 4 3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylic acid ~I, Y = B, R = i, R1 - R2 =N, R3 = ON, n = 1 A mixture of 1-hydroxy-5,6,7,8-tetrahydro-2-naphthaldehyde ( 176 ms, 1 mmol ) , malonic acid ( 208 mg, 2 mmol ) , piperidine (85 rr~g, 1 rr,~ol) and pyridine (1 ml) ere heated at 100°C for 3 h and at influx for % h.
The mixture is then cooled and poured ontoice and hydrochloric acid. The precipitated material is separated by filtration and then recrystallized from ethanol thus giving pure title compound in 80/ yield (174 mg).
C13H1403 talc. :C 71.54 H 6.46 found :C 71.35 H 6.30 MS m/z :218 IR cm 1 (KBr) :3300 - 2500 (COON, OH), 1690 (COON), 1640 (C = C) i . - 26 -Example 5 2-(4-hydroxyphenyl)-3-(naphth-2-yl)acrylic acid [I, Y = A, R = i, R2 :_ H, R3 = OH, n = zero) A mixture of 2-naphthaldehyde(i56 mgr 1 mmol), 4-hydroxyphenylacetic acid (152 mg, 1 mmol), triethylamine (101 mg, 1 mmol) and acetic anhydride (510 mg , 5 mmol) are heated for 5 h at 100°C.
After cooling, the mixture is treated with diluted hydrochloric acid and then extracted with ethylacetate. The organic layer is separated and reextracted with diluted sodium hydroxide solution. The aqueous phase is separated and the raw product isolated by precipitation with hydrochloric acid. Pure title compound is obtained by crystallization from isopropanol in 60% yield (174 mg)..
1!~ C1~H1403-c2lc.: C 78.60 H 4.86 found . C 78.69 Y. 4.89 MS m/z . 29G
IR cm 1 (KBr): 3600 - 2500 (OH, COOH), 1680 (COOH), 1600 1585, 1510 (C = C) 2C By proceeding analogously the following compounds can be prepared:

2-(4-hydroxyphenyl)-3-(naphth-1-yl)acrylic acid;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-1-yl)acrylic acid; and 2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-2-yl)acrylic acid.

n _ 28 _ Example 6 2-(4-hydroxyphenyl)-3-(naphth-2-yl)acrylamide LI , Y = A, R = i , R2= H 1 R3 = NH2 , n = zero A mixture of 2-naphthaldehyde (156 mg, 1 mmol),4-hydiroxyphenylacetic acid (152 mg, 1 mmol), triethylamine (101 mg, 1 mmol) and acetic anhydride (510 mg, 5 rrrrnl) are heated for 5 h at 100°C. The mixture is treated with diluted hydrochloric acid after cooling and then extracted with ethylacetate. The organic layer is. extracted with sodium hydroxide solution. After separation of the aqueous phase the raw carboxilic acid is isolated by precipitation wl~
hydrochloric acid.
The raw carboxylic acid is transformed in its acid chloride by treatment with thionyl chloride (1190 mg, 10 mmol) in boiling benzene (5 ml) for 2 h. After evaporation to dryness under vacuum the raw acid chloride is transformed to the amide by reaction with diluted ammonium hydroxide at room temperature for 1 h. The raw product is obtained by filtration, washing and drying under vacuum. Crystallization from isopropanol furnishes pure title compound in 50% yield (145 mg).
C19H15N02 calc. .~ 78.87 H 5.23 N 4.84 found . C 78.71 H 5.09 N 4.65 MS m/z . 289 IR cm 1 (KBr) . 3600 - 3100 (OH, NH), 1650 (CONH) 1610, 1560, 1510 (C = C) According to the above described procedure tho following compounds can be prepared:
2-(4-hydroxyphenyl)-3-(naphth-1-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-1-yl)acrylarnide_; and 2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
~xample 7 2-(4-hydroxyphenyl)-3-(naphth-2-yl)acrylonitrile (I, Y = A, R = j, R2 = H, n = ze~ro~
To a solution of 2-naphthaldehyde (156 mg, 1 mmol) and 4-hydroxybenzylcyanide (133 mg, 1 mmol) in dry ethanol (2 ml) is added portionwise under cooling sodium ethoxide (204 mg, 3 rnmol ) and the resulting solution,/maintained for 96 h at r~ocm temperature, Then the solution is poured onto a mixture of ice and diluted _.. -- --- CA 02053253 2001-08-13 hydrochloric acid. The precipitate formed is filtered off, washed with ice-cooled aqueous ethanol and dried in a vacuum- oven.
Thus, pure title compound is obtained in 80% yield (217 mg).
C19H13N0 calc. C 84.11 H 4.83 N 5.16 found C 83.91 H 4.87 N 4.B6 MS m/z . 271 IR cm 1 (KBr) . 3340 (OH), 2220 (CN), 1605, 1585, 1510 (C=C).
Example 8 2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide [I, Y = B, R = a, R1 = R2 = H, R3 = NH2, n = 11 The starting material for this de-etherification example is 2-cyano-3-(1-methoxy-5,6,7,8-tetrahydronaphth-2-yl) acrylamide, which can be obtained according to the procedure described in Example 1.
To a stirred solution of 2-cyano-3-(1-methoxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide (256 mg, 1 mmol) in anhydrous dichloromethane (10 ml) is added at -78°C under nitrogen, over a period of 10 min, a 1.0 M solution of boron tribromide in dichloromethane (3 ml, 3 mmol). The resulting mixture is stirred for another 1 h at -7B°C and then allowed to warm to room temperature. After stirring for 1.5 h at 20-25°C the mixture is cooled to -10°C and then quenched by the dropwise addition of water (10 ml) over a 10-min period. After ab dition of ethylacetate (10 ml) the organic layer is separated, washed with water, dried with Na2S04 and evaporated under vacuum to dryness. The residue is crystallized from ethanol thus giving 169 mg of pure title compound (yield 7096).
C14H14N202 talc. C 69.40 H 5.82 N 11.56 found C 69.30 H 5.85 N 11.41 MS m/z . 242 H
IR cm 1 (KBr) . 3500 - 3100 (I~IK,OH), 2210 (CN), :1685 ( CONI~2 ) , 1610 1590, 1560 According to the above described procedure and starting from the corresponding phenolic methylether,the compounds mentioned in Examplesl,2 and 3 can be obtained.
Example 9 2-cyano-3-(1-acetoxy-5,6,7,8-tetra.hydronaphth-2-yl)acrylamide [I-Y = B, R = a, R1 - COCH3, R2 = H, R3 = NH2, n = 1~
The starting material for this acylation example is 2-cyano--3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl) acrylamide, which may be obtained according to the procedure described in example 1.
To a cooled solution of 2-cyano-3-( 1-hydroxy-5, 6, 7, 8~.etrahydronaphth_ -2-yl)acrylamide(242 mg, 1 mmol in dry pyridine (0.5 ml) is added acetic anhydride (204 mg, 2 mmol) and the mixture maintained at 0-5° overnight. There upon the nixture is concentrated under vacuum, the residue dissolved in dichloromethane, the organic layer washed with~water and then evaporated under reduced pressure. The crude product is crystallized from chloroform/methanol to yield pure title compound in 90~ yield (256 rng).
C16H16N203 calc: C 67.59 H 6.67 N 9.85 found: C 6',x.41 H 5.45 N 9.71 MS m/z . 284 IR cm 1(KBr) : 3300t320C) (NI-:) , 2200 (CN) , 1750 '(CH3C00) , 1690 ( COT;H2 ) , 1610, 1590, 1560 According to the above described procedure the phenols obtained in E xamples 1 to ,9 can be transformed into the corresponding C2~6 ~~oyl derivatives.
Example 10 Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows:
composition (for 10000 tablets):

2-cyano-3-(1-hydroxynaphth-2-yl)acrylamide 250 g Lactose 800 g Corn starch 415 g Talc powder 30 g Magnesium stearate 5 g The_ 2-cyano-3-(1-hydroxynaphth-2-yl)acrylamide, the lactose and half the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size.
Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate are added, carefully mixed and processed into tablets.
Example 11 Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.
Composition f or 500 capsules:
2-cyano-3-(3-hydroxynaphth-2-yl)acrylamide SO g Lactose 80 g Corn starch 5 g Magnesium stearate 5 g This formulation is encapsulated in two-piece h and gelatin capsules and dosed at 0.200 g for each capsule:

Claims (8)

-34-
1. A compound of general formula (I) wherein Y is a mono-or bicyclic ring system chosen from (A) and (B), R is a group of formula (a), (b), (c), (d), (i) or (j) in which R3 is -OH or -NH2;
R1 is hydrogen, C1-C6 alkyl or C2-C6 alkanoyl; R2 is hydrogen, halogen, cyano or C1-C6 alkyl;
n is zero or an integer of 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A) and it is zero, 1 or 2 when Y is a ring system (B); or a pharmaceutically acceptable salt thereof; and wherein each of the substituent R, OR1 and R2 may be independently on either of the aryl moieties of the bicyclic ring system (A) whereas only the benzene moiety may be substituted in the bicyclic ring system (B); and with the provisos that:
(i) when Y is a ring system (A), R is other than a group (a), (b) or (d); and (ii) the compound of formula (I) is not 1,2,3,4-tetrahydro-5-naphthalene acrylic acid, or 1,2,3,4-tetrahydro-6-naphthalene acrylic acid.
2. A compound of formula (I), according to claim 1, wherein Y is a monocyclic or bicyclic ring system chosen from (A) and (B) as defined in claim 1;
R is a group of formula (a), (b), (c), (d), (i) or (j) as defined in claim 1;
R1 is hydrogen, C1-C4 alkyl or C2-C4 alkanoyl;
R2 is hydrogen; and n is as defined in claim 1; or a pharmaceutically acceptable salt thereof.
3. A compound of formula (I), according to claim 1, wherein Y is a bicyclic ring system of formula (A) or (B) as defined in claim 1; R is a group of formula (a), (d), (i) or (j), as defined in claim 1; R1 and R2 are hydrogen; and n is zero or 1; or a pharmaceutically acceptable salt thereof.
4. A compound selected from the group consisting of the following which, when appropriate, may be either Z- or E-diastereoisomers or Z,E- mixtures of said diastereoisomers;
2-cyano-3-(2-hydroxynaphth-1-yl)thioacrylamide;
2-cyano-3-(3-hydroxynaphth-1-yl)thioacrylamide;
2-cyano-3-(4-hydroxynaphth-1-yl)thioacrylamide;
2-cyano-3-(1-hydroxynaphth-2-yl)thioacrylamide;
2-cyano-3-(3-hydroxynaphth-2-yl)thioacrylamide;
2-cyano-3-(4-hydroxynaphth-2-yl)thioacrylamide;
2-(4-hydroxyphenyl)-3-(naphth-1-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(naphth-2-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(naphth-1-yl)acrylic acid;
2-(4-hydroxyphenyl)-3-(naphth-2-yl)acrylic acid;

2-cyano-3-(2-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylamide;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylamide;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylamide;
2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-cyano-3-(2-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylic acid;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylic acid;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)acrylic acid 2-cyano-3-(2-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-1-yl)thioacrylamide;
2-cyano-3-(1-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)thioacrylamide;
2-cyano-3-(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)thioacrylamide;
2-cyano-3-(4-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)thioacrylamide;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-1-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-2-yl)acrylamide;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-1-yl)acrylic acid;
2-(4-hydroxyphenyl)-3-(5,6,7,8-tetrahydronaphth-2-yl)acrylic acid;

and the pharmaceutically acceptable salts thereof.
5. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, in the form of single isomers thereof, or a mixture of these isomers, the process comprising the condensation of an aldehyde of formula (II) wherein Y, R1, R2 and n are as defined in claim 1,with a compound of formula (a'), (b'), (c'), (d'), (i') or (j') respectively, (a') (b') (c') (d') wherein R3 is as defined in claim 1; and, A., optionally converting the compound of formula (I) thus obtained into a different compound of formula (I) by (a) de-etherifying the compound of formula (I) wherein one or more R1 substituents are C1-C6 alkyl to form the corresponding different compound of formula (I) wherein one or more R1 substituents are hydrogen; by (b) acylating the compound of formula (I) wherein one or more R1 substituents are hydrogen to form the corresponding different compound of formula (I) wherein one or more R1 substituents are C2-C6 alkanoyl; or by (c) converting the compound of formula (I) in which R is a group of formula -CH=C(CN)-COOH or -CH=CH-COOH into the corresponding different compound of formula (I) in which R
is a group of formula -CH=C(CN)-CONH2 or -CH=CH-CONH2, respectively; and/or; B., optionally converting the compound of formula (I) into a pharmaceutically acceptable salt thereof and/or; C., optionally converting a salt into a free compound and/or; D., optionally separating a mixture of isomers of the compound of formula (I) into the single isomers.
6. A pharmaceutical composition containing a suitable carrier and/or diluent and, as active principal, a compound of formula (I):

wherein Y is a mono- or bicyclic ring system chosen from (A) and (B):
R is a group of formula (a), (b), (c), (d), (i) or (j) in which R3 is -OH or -NH2; R1 is hydrogen, C1-C6 alkyl or C2-C6 alkanoyl; R2 is hydrogen, halogen, cyano or C1-C6 alkyl; n is zero or an integer of 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A) and it is zero, 1 or 2 when Y is a ring system (B); or a pharmaceutically acceptable salt thereof; and wherein each of the substituent R, OR1 and R2 may be independently on either of the aryl moieties of the bicyclic ring system (A) whereas-only the benzene moiety may be substituted in the bicyclic ring system (B); and with the proviso that when Y is a ring system (A), R is other than a group (a), (b) or (d).
7 . A compound of formula (I) wherein Y is a mono- or bicyclic ring system chosen from (A) and (B):
R is a group of formula (a), (b), (c), (d), (i) or (j) in which R3 is -OH or -NH2; R1 is hydrogen, C1-C6 alkyl or C2-C6 alkanoyl; R2 is hydrogen, halogen, cyano or C1-C6 alkyl; n is zero or an integer of 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A) and it is zero, 1 or 2 when Y is a ring system (B); or a pharmaceutically acceptable salt thereof; and wherein each of the substituent R, OR1 and R2 may be independently on either of the aryl moieties of the bicyclic ring system (A) whereas only the benzene moiety may be substituted in the bicyclic ring system (B); and with the proviso that when Y is a ring system (A), R is other than a group (a), (d) or (d); for use as a tyrosine kinase inhibitor.
8. Use, in the preparation of a medicament for use as a tyrosine kinase inhibitor, of a compound cf formula (I):
wherein Y is a mono- or bicyclic ring system chosen from (A) and (B) R is a group of formula (a), (b), (c), (d), (i) or (j) (b); or a pharmaceutically acceptable salt thereof; and in which R3 is -OH or -NH2;
R1 is hydrogen, C1-C6 alkyl or C2-C6 alkanoyl; R2 is hydrogen, halogen, cyano or C1-C6 alkyl;
n is zero or an integer of 1 to 3; n is zero or an integer of 1 to 3 when Y is a ring system (A) and it is zero, 1 or 2 when Y is a ring system (B); or a pharmaceutically acceptable salt thereof; and wherein each of the substituent R, OR1 and R2 may be independently on either of the aryl moieties of the bicyclic ring system (A) whereas only the benzene moiety may be substituted in the bicyclic ring system (B).
CA002053253A 1990-02-28 1991-02-26 New aryl-and heteroarylethenylene derivatives and process for their preparation Expired - Fee Related CA2053253C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9004483.5 1990-02-28
GB909004483A GB9004483D0 (en) 1990-02-28 1990-02-28 New aryl-and heteroarylethenylene derivatives and process for their preparation
PCT/EP1991/000350 WO1991013055A2 (en) 1990-02-28 1991-02-26 New aryl- and heteroarylethenylene derivatives and process for their preparation

Publications (2)

Publication Number Publication Date
CA2053253A1 CA2053253A1 (en) 1991-08-29
CA2053253C true CA2053253C (en) 2005-04-26

Family

ID=10671744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002053253A Expired - Fee Related CA2053253C (en) 1990-02-28 1991-02-26 New aryl-and heteroarylethenylene derivatives and process for their preparation

Country Status (20)

Country Link
US (3) US5374652A (en)
EP (2) EP0662473B1 (en)
JP (2) JP3152434B2 (en)
KR (1) KR920701136A (en)
AT (2) ATE184000T1 (en)
CA (1) CA2053253C (en)
DE (2) DE69131581T2 (en)
DK (1) DK0470221T3 (en)
ES (2) ES2137386T3 (en)
FI (1) FI915010A0 (en)
GB (1) GB9004483D0 (en)
GR (1) GR3018891T3 (en)
HU (1) HU210791B (en)
IE (1) IE73666B1 (en)
IL (1) IL97049A (en)
NZ (1) NZ237182A (en)
PT (1) PT96897B (en)
RU (1) RU2091369C1 (en)
WO (1) WO1991013055A2 (en)
ZA (1) ZA911441B (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
AU662480B2 (en) * 1990-04-16 1995-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5587385A (en) * 1991-12-24 1996-12-24 Farmitalia Carlo Erba S.R.L. Arylidene-heterocyclic derivatives and process for their preparation
EP0549348A1 (en) * 1991-12-24 1993-06-30 PHARMACIA S.p.A. Arylidene-heterocyclic derivatives, process for their preparation and their use as tyrisine kinase inhibitors
GB9204945D0 (en) * 1992-03-06 1992-04-22 Erba Carlo Spa 3-aryl-glycidic ester derivatives and process for their preparation
JPH08503450A (en) * 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 2-Thioindole (selenoindole) and related disulfides (selenides) that inhibit protein tyrosine kinases and have antitumor properties
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5449788A (en) * 1994-01-28 1995-09-12 Catalytica, Inc. Process for preparing 2-oxindole-1-carboxamides
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
ATE308520T1 (en) * 1996-08-23 2005-11-15 Sugen Inc INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR TREATING DISEASES
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
WO1998024432A2 (en) * 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
CA2291750A1 (en) 1997-05-28 1998-12-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US20040067531A1 (en) * 1997-08-20 2004-04-08 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
JP2002504529A (en) 1998-02-27 2002-02-12 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Disubstituted lavendustine A analogs and pharmaceutical compositions containing these analogs
JP2002507598A (en) * 1998-03-26 2002-03-12 スージェン・インコーポレーテッド A family of heterocyclic compounds for regulating tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP1082305A4 (en) 1998-05-29 2001-09-26 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2002522452A (en) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド Regulator of protein kinase 3-methylidenyl-2-indolinone
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
CA2354873A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
JP2002532503A (en) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー 4,5-Pyrazinooxindole as a protein kinase inhibitor
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
WO2000056709A1 (en) * 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
PT1255752E (en) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Pyrrole substituted 2-indolinone protein kinase inhibitors
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
EP1265849B1 (en) * 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
MXPA02012560A (en) 2000-06-30 2003-05-14 Elan Pharm Inc Compounds to treat alzheimer s disease.
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US6633484B1 (en) 2000-11-20 2003-10-14 Intel Corporation Heat-dissipating devices, systems, and methods with small footprint
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
PE20030062A1 (en) 2001-05-30 2003-02-08 Sugen Inc ARALKYLSULFONIL-3- (PYRROL-2-ILMETILIDEN) -2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
AR038957A1 (en) * 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
BR0213185A (en) 2001-10-10 2004-09-14 Sugen Inc 3- [4- (Substituted Heterocyclyl) -pyrrol-2-ylmethylidene] 2-indolinone derivatives as kinase inhibitors
US20040176372A1 (en) * 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
PT1567112E (en) * 2002-11-22 2009-01-08 Smithkline Beecham Corp Thiazolidin-4-ones for inhibiting hyak3 proteins
AU2004298511B2 (en) 2003-12-11 2011-08-11 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
PE20070083A1 (en) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5Z) -5- (6-QUINOXALINYL METHYLIDENE) -2 - [(2,6-DICHLOROPHENYL) AMINO] -1,3-THIAZOL-4 (5H) -ONE
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
CN100510679C (en) * 2007-08-24 2009-07-08 中国北方车辆研究所 Planet wheel bearing test device
UA103492C2 (en) 2008-07-08 2013-10-25 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Inhibitors of proliferacii and activating of vection of signal and activator of transcription (stats)
CN102711765A (en) 2009-11-16 2012-10-03 加利福尼亚大学董事会 Kinase inhibitors
CN102115469A (en) * 2011-03-21 2011-07-06 浙江大学 Preparation method for indoline-2-one derivative and application of same
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056790A (en) * 1960-01-08 1962-10-02 Wisconsin Alumni Res Found 8-ro-2-quinoline acrylic acid and lower alkyl esters thereof
DE3310891A1 (en) * 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim NEW INDOLINON (2) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS
US4971996A (en) * 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
GB8727099D0 (en) * 1987-11-19 1987-12-23 Cellena Cell Eng A G Compositions containing melantonin/homologues
FI91062C (en) * 1988-12-28 1994-05-10 Eisai Co Ltd Process for the preparation of naphthalene derivatives useful as a medicament
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation

Also Published As

Publication number Publication date
RU2091369C1 (en) 1997-09-27
US5627207A (en) 1997-05-06
JP2000204070A (en) 2000-07-25
US5488057A (en) 1996-01-30
HU913626D0 (en) 1992-03-30
IE910664A1 (en) 1991-08-28
DE69115379T2 (en) 1996-05-15
KR920701136A (en) 1992-08-11
EP0662473A1 (en) 1995-07-12
ES2137386T3 (en) 1999-12-16
GB9004483D0 (en) 1990-04-25
GR3018891T3 (en) 1996-05-31
IL97049A (en) 1995-10-31
HU210791B (en) 1995-07-28
CA2053253A1 (en) 1991-08-29
JPH04506081A (en) 1992-10-22
NZ237182A (en) 1993-12-23
EP0662473B1 (en) 1999-09-01
US5374652A (en) 1994-12-20
DE69115379D1 (en) 1996-01-25
ATE184000T1 (en) 1999-09-15
JP3152434B2 (en) 2001-04-03
AU652740B2 (en) 1994-09-08
EP0470221A1 (en) 1992-02-12
IE73666B1 (en) 1997-07-02
IL97049A0 (en) 1992-03-29
DE69131581D1 (en) 1999-10-07
PT96897B (en) 1998-07-31
HUT59081A (en) 1992-04-28
DE69131581T2 (en) 2000-01-20
ES2083569T3 (en) 1996-04-16
ATE131470T1 (en) 1995-12-15
WO1991013055A2 (en) 1991-09-05
AU7241291A (en) 1991-09-18
ZA911441B (en) 1991-11-27
WO1991013055A3 (en) 1991-10-31
JP3292845B2 (en) 2002-06-17
PT96897A (en) 1991-10-31
EP0470221B1 (en) 1995-12-13
FI915010A0 (en) 1991-10-23
DK0470221T3 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
CA2053253C (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
US5397787A (en) Vinylene-azaindole derivatives
US5656654A (en) Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5719135A (en) Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
US5652250A (en) N-substituted β-aryl- and β-heteroaryl-α-cyanoacrylamide derivatives and process for their preparation
US5122537A (en) Arylvinylamide derivatives and pharmaceutical use
US6147073A (en) Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors
US5436235A (en) 3-aryl-glycidic ester derivatives
AU652740C (en) New aryl- and heteroarylethenylene derivatives and process for their preparation
CA2163115C (en) N-substituted beta-aryl- and beta-heteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
MXPA95004895A (en) Derivatives of beta-aril- and beta-heteroaril-alpha-cianoacrilamide n-substitute and process to supreparate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed